Loading...
Loading...
Browse all stories on DeepNewz
VisitCassava's Simufilam Fails Phase 3 Alzheimer's Trial; Company Discontinues Trials, Shares Plunge 85%
Nov 25, 2024, 12:55 PM
Cassava Sciences announced that its Alzheimer's drug, Simufilam, failed to meet co-primary, secondary, and exploratory endpoints in the Phase 3 ReThink-ALZ trial. The study showed that Simufilam did not demonstrate a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's disease. Despite Simufilam demonstrating an overall favorable safety profile, the company plans to discontinue the second Phase 3 ReFocus-ALZ trial and the Open Label Extension study. Following the announcement, trading of Cassava Sciences' stock was halted, and the stock price dropped by over 85% pre-market. The company plans to present detailed results at a future medical meeting.
View original story
Markets
No • 50%
Yes • 50%
Official press releases from Cassava Sciences or reputable news outlets
No • 50%
Yes • 50%
Announcements from Cassava Sciences or coverage of major medical conferences
Yes • 50%
No • 50%
Stock market data from financial platforms like Bloomberg or Yahoo Finance
Less than $100 million • 25%
Over $1 billion • 25%
$500 million to $1 billion • 25%
$100 million to $500 million • 25%
Financial data from platforms like Bloomberg or Yahoo Finance
Seek partnerships or mergers • 25%
Other strategic move • 25%
Announce a new drug development • 25%
Focus on non-Alzheimer's projects • 25%
Official announcements from Cassava Sciences or reputable news outlets
No significant impact • 25%
Results lead to renewed interest • 25%
Results confirm initial failure • 25%
Mixed reception from the scientific community • 25%
Reports from the medical meeting or official publications of the trial results